New therapy Fig | carbalive

top of page

Home
- Liver disease
- Current therapies
The CARBALIVE project
Consortium Partners
News
- Press Release
Publications
Co-ordinator contact
Members Pages
More

Use tab to navigate through the menu items.

Disclaimer as of 18 May 2022: The data relating to CARBALIVE described on the EC website should be considered a “preliminary analysis”’ and although it is based on a fully audited and monitored Clinical Study, the trial was terminated on March 26th 2020, due to the pandemic preventing patient travel to hospital for mandatory safety assessments. 31 of a possible 58 patients had been enrolled. The 31 patients included the entire cohort taking the lower of two doses. Since treatment of this cohort was completed, the data generated formed the basis of evidence gathered and the conclusions drawn. Further details on the CARBALIVE clinical study outcomes can be found on https://yaqrit.com/news/the-carbalive-consortium-announces-positive-results-of-a-phase-2-equivalent-trial-of-engineered-macroporous-carbons-as-a-novel-treatment-for-cirrhosis/ with details of the clinical study protocol on the ClinicalTrials.gov web site https://clinicaltrials.gov/ct2/show/record/NCT03202498. The results underwent QC review on February 14th 2022 and returned to the sponsor on April 15th 2022 to address any concerns raised. Once these have been addressed, the results will be made public and a copy of the Clinical Study Report will be available on request from the Sponsor: Yaqrit Limited (www.yaqrit.com)

bottom of page